top of page


European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer
The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.

nuaxia
3 hours ago2 min read


FDA approves first-in-class targeted therapy daraxonrasib for metastatic pancreatic cancer
The approval introduces the first RAS(ON) inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with a KRAS G12X mutation, establishing a new biomarker-directed option for one of the hardest-to-treat cancers.

nuaxia
Aug 272 min read


A Standing Ovation for a New Chapter in Pancreatic Cancer
Daraxonrasib, KRAS G12D, and the ASCO26 Signal That Broke a Long Silence

nuaxia
Jun 34 min read


FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer
Wearable TTFields device now authorised in combination with chemotherapy following Phase III PANOVA-3 trial demonstrating overall survival benefit.

nuaxia
Feb 161 min read
bottom of page